8-K: Aprea Therapeutics Announces Positive Preliminary Safety Data for WEE1 Inhibitor APR-1051

Aprea Therapeutics reports that its WEE1 inhibitor, APR-1051, shows promising preliminary safety results in an ongoing Phase 1 clinical trial, with no hematologic toxicity observed.

Summary

• Aprea Therapeutics has released preliminary safety data for its oral WEE1 inhibitor, APR-1051, from the ongoing Phase 1 ACESOT-1051 clinical trial.
• The trial is evaluating APR-1051 as a monotherapy for patients with advanced solid tumors and cancer-associated gene alterations.
• The dose escalation part of the study is ongoing and plans to enroll up to 39 patients across 8 cohorts, with doses ranging from 10 mg to 150 mg daily.
• Initial data from the first three cohorts, using subtherapeutic doses of 10mg, 20mg and 30mg, show that APR-1051 is safe and well-tolerated.
• No hematologic toxicity was observed, with hemoglobin, hematocrit, and platelet counts remaining stable or slightly increasing.
• There were no signs of neutropenia, and white blood cell and neutrophil counts trended upwards.
• All adverse events recorded were Grade 1 and 2, with only one Grade 1 event possibly related to APR-1051.
• No QT prolongation was observed.
• Three patients have been dosed, with data available for two; one patient had disease progression at 49 days, and another withdrew after 36 days, while the third patient is still being dosed.
• The company expects to confirm the favorable safety profile as they move to higher doses and hopes to generate preliminary efficacy data during 2025.

Sentiment

Score: 7

Explanation: The document presents positive preliminary safety data for a new drug candidate, which is encouraging. However, it is still early in the clinical trial process, and efficacy data is not yet available. The sentiment is cautiously optimistic.

Positives

• APR-1051 has demonstrated a favorable safety profile in early clinical trials.
• The drug has shown no hematologic toxicity, which is a positive sign for its tolerability.
• The absence of QT prolongation is a key advantage over other WEE1 inhibitors.
• The company is actively enrolling patients at three sites in the U.S.
• The preliminary findings are considered promising by the medical community.

Negatives

• Data is only available for two of the three patients dosed so far.
• One patient experienced disease progression after 49 days of treatment.
• Another patient withdrew from the study after 36 days of treatment.
• The study is still in the early dose escalation phase, and efficacy data is not yet available.

Risks

• The study is still in its early stages, and the safety profile may change as higher doses are tested.
• Efficacy data is not yet available, and there is no guarantee that the drug will be effective.
• The trial is dependent on patient enrollment, which could be a challenge.
• The company's ability to fully fund the clinical trials is subject to change.
• The preliminary results are not necessarily indicative of the final results of the ongoing clinical trials.

Future Outlook

The company expects to confirm the favorable safety profile of APR-1051 as they move to higher doses in the ACESOT-1051 trial and hopes to generate preliminary efficacy data from the study during 2025.

Management Comments

• Philippe Pultar, MD, Senior Medical Advisor and Lead of WEE1 Clinical Development at Aprea, stated that the preliminary data are encouraging, showing that APR-1051 is safe and well-tolerated.
• Anthony Tolcher M.D., Founder of Next Oncology, commented that the preliminary findings are promising and they are encouraged by the minimal toxicity in the patients treated so far.

Industry Context

This announcement is relevant to the broader oncology field, where there is a significant need for new and effective treatments for advanced solid tumors. The development of WEE1 inhibitors is an area of active research, and Aprea's APR-1051 is a potential competitor in this space.

Comparison to Industry Standards

• Other companies are also developing WEE1 inhibitors, such as AZD1775 (Adavosertib) by AstraZeneca, which has shown some efficacy but also has known toxicities.
• Aprea's APR-1051 is differentiated by its selectivity for WEE1 and the absence of off-target inhibition of PLK or QT prolongation, which are issues with some other WEE1 inhibitors.
• The preliminary safety data for APR-1051 appears to be competitive with other WEE1 inhibitors in early clinical development, but further data is needed to confirm its efficacy and long-term safety.

Stakeholder Impact

• Shareholders may view the positive safety data as a positive development for the company.
• Patients with advanced solid tumors may benefit from the development of a new treatment option.
• Employees of Aprea may be encouraged by the progress of the clinical trial.
• The medical community may be interested in the potential of APR-1051 as a new cancer therapy.

Next Steps

• The company will continue the dose escalation part of the Phase 1 trial, enrolling up to 39 patients.
• They will move to higher doses to confirm the favorable safety profile.
• The company plans to generate preliminary efficacy data from the study during 2025.
• Additional sites will be added to the study.

Key Dates

Keywords

APR-1051, WEE1 inhibitor, oncology, clinical trial, cancer therapeutics, synthetic lethality, Phase 1, safety, hematologic toxicity, solid tumors